PF 4991532

Drug Profile

PF 4991532

Alternative Names: PF-04991532; PF-4991532

Latest Information Update: 14 Aug 2012

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 May 2012 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA and Japan (NCT01469065)
  • 22 May 2012 Pfizer completes enrolment in a phase I trial in Type-2 diabetes mellitus in USA and Japan (NCT01469065)
  • 10 May 2012 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top